Top doctors discuss Afrezza for Medscape

Phenomenal medscape presentation on inhaled insulin and benefits of faster insulin. I’m still listening to it now (and it’s quite long) so comments to follow. Worth a listen. I would consider this must hear material for anyone whose ever been interested in benefits of faster insulin of any kind particularly inhaled insulin
http://www.medscape.org/viewarticle/878755?src=soc_tw_diab_mscpedu_9am

This explains pretty much everything anyone would want to know about the benefits, risks, studies, history, really everything anyone would want to know about afrezza. Particularly if you have concerns… they really do a great job going through the data and explaining it in meaningful and relevant context.

3 Likes

I can’t figure out why this link is not working without a password… when accessed through twitter it works without a password

I just tweeted it to FUdiabetes… I don’t understand why it can be viewed on twitter but not here with the link copied

It must be the Medscape setup: if you access the link from Twitter they let you in, otherwise they ask for pwd:(

I’ll retweet it a few times over the next couple of days. A good opportunity for all of you guys to follow us on Twitter!

It’s not a bad idea to become a Medscape subscriber btw – it’s free.

2 Likes

Who are the medical professionals on the video? Anyone we’d know?

1 Like

Medscape is a very frequent source of information in which members here would be intertested. Membership is free and easy to obtain, and I would encourage all here to sign up.

2 Likes

I’d heard of Dr Bruce Bode in Atlanta before, the others I hadn’t heard from but was impressed with all. It’s interesting to hear because they’re physicians and the discussion is directed toward other physicians so you get an inside look at some of their perspective with things like patient compliance etc…

1 Like

When I look at the conflicts of interest disclosures, here is the run-down:

  • While Pettus was an advisor to Mannkind, and Bode received a clinical research grant from them,

  • McGill, Le and Morris have no financial links at all to Mannkind.

  • None of the SPC committee members have any financial relationships to Mannkind.

So this is a very legit review, which should be very unbiased on the whole – very cool. In fact, I believe that, in most states, physicians can receive continuing education credits for viewing this video.

2 Likes

Wish more of them would do so. Did you listen to the whole thing?

Not yet, no time today – we had a major flooding event overnight, and there is a thick layer of water in my basement. Just spent 8 hours hauling everything I can out of there… Not how I’d like to spend the weekend :slight_smile:

3 posts were split to a new topic: Darn flood – and no time for forum :frowning:

transcript is here https://docs.google.com/document/d/1i8Pn9D7mgblNweprBovjP-c9BjnYSwX7SNXE_Dgdb34/edit

3 Likes

@Gus, the transcript is GREAT, thank you! I am reading it right now. I will put a few small snippets online in this thread.

1 Like

From the transcript

  • About endos offering and prescribing Afrezza

“Dr. Bode: The problem is most people (ENDOs) out there, never give this (AFREZZA) an option. They worry about the pulmonary safety opinion. They never worried about pulmonary safety, but that’s their job. Their job is to make sure that whatever medication you give that that it’s safe. And there’s clearly, from Lung Biologists and Pulmonologists and Oncologists, the (AFREZZA) is safe.”

  • About Afrezza cough

“Dr. Jeremy Pettus
The only thing I’ve noticed, is that people, when they first start to do these dramatic inhalations, they suck vigorously and really, I feel that they can produce a cough. But it really does not take a lot of force. It’s more a calm, kind of like gentle inhalation and still get the amount of material. Like Bruce said, I wanted to say, most people used, you will most likely cough for the 1st or 2nd time, but then it goes away.
Dr. Janet McGill
Yeah, you read e-mails. People do overdo, you’re right. Have them calm down a little bit. Aim (inhaler) that it does not hit the top ( of the mouth)…(aim for the throat).”

  • About the lack of tail in Affrezza (no lows long after inhalation)

“Dr. Janet McGill
"We use it (AFREZZA) also on our exercisers, who really cannot handle a tail on their insulin. Some of them are wearing some pumps and use the inhaled insulin (AFREZZA) for both meals and corrections, because the tail effect is a big problem for them.”

  • Lung safety of Afrezza

“Question: Safety of Inhaled Insulin (AFREZZA)
Reply: Dr. Bruce Bode: One thing, I think, is the safety. Most ENDOs won’t prescribe because of the safety. I have been around enough of these lung biologists and experts, because I’ve been involved with them for the last 10 years. They’ll convince you “it’s perfectly safe”. And the other thing, this drop of 40 mililiters, it’s like me sitting here and I go back like this, I drop 40 mililiters of my FEV1 by just lying down. That’s less that one per cent, one and a half per cent of your FEV1 overall. Lung Function: That’s the safety. But that’s hard for people to get over.”

  • Lung cancer incidence in the study

"Question: Give the latest post marketing data on lung cancer:
Dr. Bode, Reply: “As far as I know, there’s no reported (cases). The ones who had lung cancer, there were a total of four, 2 during and 2 afterwards. These people - 2 of them had long standing history of smoking. One person only used it (AFREZZA) a very short time, less than a few weeks.”

2 Likes

This is just selected extracts it appears… I think far better to listen to the audio in this case as it flows much better

2 Likes

They also point out in a different part of the audio that upon later followup what had initially appeared to be a statistically significant decrease of fev1 in the type 1 diabetes group studied had returned to baseline even with continued use

2 Likes

@Sam Thanks for the link, excellent presentation.
First thing I’m going to ask my endo for at my next visit is an FEV1 to see if I can take Afrezza even with my mild to moderate asthma.

3 Likes

It will be interesting to hear what they say… they did spend some time discussing the asthma counter indication

2 Likes

Try the link in the following twitter:

2 Likes

Sam, agree with you. Much more information if one actually listens to the whole program (compared with just reviewing the summary). And as Michael has pointed out, registration with Medscape Education is free. It took me just one minute to register for an account. Below is the twitter message from Medscape itself on this presentation. I think the audio quality of this linked broadcast is better than the one I provided above.

1 Like